How do you manage asparaginase toxicity in your AYA patients with ALL?

During the 8th Annual Meeting of the Society of Hematologic Oncology (SOHO), the ALL Hub spoke to Kjeld Schmiegelow, Rigshospitalet, Copenhagen, DK. We asked, How do you manage asparaginase toxicity in adolescent and young adult (AYA) patients with ALL?

In this podcast, Schmiegelow gives an overview of the challenges clinicians face when treating AYAs with asparaginase for ALL. He elaborates on the five main toxicities related to the drug, liver dysfunction-associated parameters, hypersensitivity reactions, and clinical intolerance symptoms like vomiting, asparaginase-associated pancreatitis, pulmonary/CNS thromboembolism, and osteonecrosis. Finally, Schmiegelow discusses the findings of a study about preventing the risks and occurrence of these toxicities.